Phuturdex › Diseases › Adrenal cortex neoplasm
Drugs in development · updated 30 October 2026
Adrenal cortex neoplasm: drugs in development
As of 30 October 2026 there are 7 active clinical trials (recruiting or ongoing, phases I–III) on 12 drugs for adrenal cortex neoplasm. One is experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PDS01ADC | II | 1 | NCT05286814 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PembrolizumabKEYTRUDA, MK-3475 | II | 2 | NCT02721732 |
| Cabozantinib S-malateCabometyx®, Cometriq® | II | 1 | NCT06006013 |
| DexamethasoneDexametasone, Dextenza | II | 1 | NCT05286814 |
| FloxuridineFUDR | II | 1 | NCT05286814 |
| LutatheraLutetium Lu 177 Dotatate, 177Lu-DOTATATE | I–II | 1 | NCT06607692 |
| OlaparibAZD2281, Lynparza® | I–II | 1 | NCT06607692 |
| RelacorilantLifyorli (Copackaged)®, Lifyorli® | II | 1 | NCT03604198 |
| CarfilzomibKitprozy®, Kyprolis® | I | 1 | NCT07715903 |
| CyclophosphamideCyclophosphamid, Cytoxan | I | 1 | NCT04897321 |
| FludarabineFludara, FLUDARABIN | I | 1 | NCT04897321 |
| MesnaUromitexan, Mesnex® | I | 1 | NCT04897321 |
Sorted by most advanced phase and number of active trials.
All 12 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Adrenocortical carcinoma 28 drugs
- Paraganglioma 24 drugs
- Pheochromocytoma 29 drugs
- Metastasis 493 drugs
- Neuroendocrine tumor 84 drugs
- Thyroid neoplasm 99 drugs
- Desmoid Tumors 11 drugs
- Hepatocellular carcinoma 266 drugs
- Sarcoma 204 drugs
- Neuroendocrine carcinoma 55 drugs
- Melanoma 352 drugs
- Uveal melanoma 49 drugs
Broader categories
- Endocrine gland neoplasm 3 drugs
- Endocrine system disease 19 drugs
- Glandular and epithelial neoplasm 12 drugs
- Neoplasm 671 drugs
- Adenocarcinoma 111 drugs
- Carcinoma 137 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000306 “Adrenal Cortex Neoplasms”.